<DOC>
	<DOC>NCT02465203</DOC>
	<brief_summary>Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies</brief_summary>
	<brief_title>3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study</brief_title>
	<detailed_description>The purpose of this study is to follow patients from the feeder studies who have not achieved SVR24 to assess their viral activity, and to assess the changes in liver function and disease, and post-treatment safety over time.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>1. Males or females aged â‰¥18 2. Have previously completed a Novartissponsored hepatitis C study and received alisporivir or a direct antiviral agent (DAA) 3. Have not achieved SVR24 1. Use of any investigational drugs within 5 halflives of enrollment, or within 30 days of that medication, whichever is longer. 2. Previous use of any course of hepatitis C therapy since the end of the Novartissponsored hepatitis C study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatitis C, chronic</keyword>
</DOC>